Ewha University Blood Cancer Hospital Opens Cell and Gene Processing Center...Intractable Blood Cancer Treatment Options Strengthened
Oct 23, 2025
Ewha Womans University Blood Cancer Hospital (Hospital Director Moon Young-chul) recently opened a cell and gene processing center capable of 'CAR-T cell therapy' and started full-scale operation, further strengthening treatment options for incurable blood cancer patients.
CAR-T (Chimeric Antigen Receiver T) cell therapy is an immune cell therapy that effectively removes cancer cells by genetically modifying T cells, the patient's immune cells, and injecting them back into the patient. It is performed as a last-stage treatment for patients who do not respond to or do not respond to existing treatments, and among blood cancers, lymphoma of B cell origin, lymphocytic leukemia, and multiple myeloma are targeted for treatment.
Ewha Womans University Blood Cancer Hospital has established a multidisciplinary integrated medical system to operate cell and gene processing centers safely and effectively, and medical staff in infectious medicine, neurology, and intensive care units are responding quickly to various side effects and emergencies that may occur during the treatment process.
In particular, since CAR-T cell treatment is important to manage side effects such as inflammatory reactions, neurological toxicity, and cytokine release syndrome, the Ewha Womans University Blood Cancer Hospital Cell and Gene Processing Center has established a thorough protocol and safety system to prioritize patient safety. In addition, a dedicated nurse participates in all processes of treatment to solve patients' questions and share their treatment journey.
Kim Soo-kyung, director of the Cell and Gene Processing Center (Department of Diagnostic Laboratory Medicine), said "We will strive to provide safe and high-quality cell therapy to intractable blood cancer patients who do not respond to existing treatments through the operation of the cell and gene processing center."
Director of Ewha Womans University Hematologic Cancer Hospital Moon Young-cheol said, `The cell and gene processing center, consisting of professional medical staff with abundant clinical experience such as blood cancer treatment and hematopoietic stem cell transplantation, can provide customized treatment optimized for each patient"We will actively participate in the development of next-generation cell therapy as well as research on new drugs to lead the development of future blood cancer treatments." he said.
Meanwhile, Ewha Medical Center, Ewha Medical Center, Kim Han-soo, director of Ewha Medical Center, and Moon Young-chul, director of Ewha Blood Cancer Hospital, and Kim Soo-kyung, director of the Cell and Gene Processing Center, held a ceremony on the first basement floor of the main building of Ewha Medical Center (Hospital Director Kim Han-soo) on the 16th.
CAR-T (Chimeric Antigen Receiver T) cell therapy is an immune cell therapy that effectively removes cancer cells by genetically modifying T cells, the patient's immune cells, and injecting them back into the patient. It is performed as a last-stage treatment for patients who do not respond to or do not respond to existing treatments, and among blood cancers, lymphoma of B cell origin, lymphocytic leukemia, and multiple myeloma are targeted for treatment.
Ewha Womans University Blood Cancer Hospital has established a multidisciplinary integrated medical system to operate cell and gene processing centers safely and effectively, and medical staff in infectious medicine, neurology, and intensive care units are responding quickly to various side effects and emergencies that may occur during the treatment process.
In particular, since CAR-T cell treatment is important to manage side effects such as inflammatory reactions, neurological toxicity, and cytokine release syndrome, the Ewha Womans University Blood Cancer Hospital Cell and Gene Processing Center has established a thorough protocol and safety system to prioritize patient safety. In addition, a dedicated nurse participates in all processes of treatment to solve patients' questions and share their treatment journey.
Kim Soo-kyung, director of the Cell and Gene Processing Center (Department of Diagnostic Laboratory Medicine), said "We will strive to provide safe and high-quality cell therapy to intractable blood cancer patients who do not respond to existing treatments through the operation of the cell and gene processing center."
Director of Ewha Womans University Hematologic Cancer Hospital Moon Young-cheol said, `The cell and gene processing center, consisting of professional medical staff with abundant clinical experience such as blood cancer treatment and hematopoietic stem cell transplantation, can provide customized treatment optimized for each patient"We will actively participate in the development of next-generation cell therapy as well as research on new drugs to lead the development of future blood cancer treatments." he said.
Meanwhile, Ewha Medical Center, Ewha Medical Center, Kim Han-soo, director of Ewha Medical Center, and Moon Young-chul, director of Ewha Blood Cancer Hospital, and Kim Soo-kyung, director of the Cell and Gene Processing Center, held a ceremony on the first basement floor of the main building of Ewha Medical Center (Hospital Director Kim Han-soo) on the 16th.
|
This article was translated by Naver AI translator.
